Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center

Discovery and preclinical development of orally active and highly selective follicle stimulating hormone receptor agonists. Toxicological evaluations in both rat and dog were performed by Medicilon

2023-07-11
|
Page View:

58(2).pngTOP5300 is an orally active follicle stimulating hormone receptor allosteric agonist that provides a preferred treatment for over 16 million infertile women of reproductive age in low complexity methods or in high complexity methods.

TOP5300 was evaluated in standard ADME, including Cytochrome P450 inhibition, clearance and pharmacokinetic profiles. Toxicological evaluations were performed in both rat and dog as the second species according to the guidance from FDA. These assays were performed by Medicilon.

58(1).pngReference:

Selva Nataraja, et al. Discovery and Preclinical Development of Orally Active Small Molecules that Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism. Front Pharmacol. 2021 Jan 14;11:602593. doi: 10.3389/fphar.2020.602593. 


Return
Relevant News